Predictors of Visual Response to Intravitreal Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration

Abstract EN

Purpose.

To identify the predictors of visual response to the bevacizumab treatment of neovascular age-related macular degeneration (AMD).

Design.

A cohort study within the Neovascular AMD Treatment Trial Using Bevacizumab (NATTB).

Methods.

This was a multicenter trial including 144 participants from the NATTB study.

Visual outcomes measured by change in visual acuity (VA) score, proportion gaining ≥15 letters, and change in central retinal thickness (CRT) were compared among groups according to the baseline, demographic, and ocular characteristics and genotypes.

Results.

Mean change in the VA score was 9.2 ± 2.3 SD letters with a total of 46 participants (31.9%) gaining ≥15 letters.

Change in median CRT was −81.5 μm.

Younger age, lower baseline VA score, shorter duration of neovascular AMD, and TT genotype in rs10490924 were significantly associated with greater VA score improvement (P=0.028, P<0.001, P=0.02, and P=0.039, resp.).

Lower baseline VA score and TT genotype in rs10490924 were significantly associated with a higher likelihood of gaining ≥15 letters (P=0.028, and P=0.021, resp.).

Conclusions.

Baseline VA and genotype of rs10490924 were both important predictors for visual response to bevacizumab at 6 months.

This trial is registered with the Registration no.

NCT01306591.